A Phase 2 Study of Oral Difelikefalin for Moderate-to-Severe Pruritus in Subjects With Notalgia Paresthetica (KOMFORT)

Main Article Content

Brian S Kim
Robert Bissonnette
Kristine Nograles
Catherine Munera
Nilam Shah
Alia Jebara
Joshua Cirulli
Joana Goncalves
Mark Lebwohl

Keywords

notalgia paresthetica, KOMFORT, difelikefalin, phase 2, clinical trial

Abstract

N/A

References

1. Ellis C. Dermatol Pract Concept. 2013;3:3-6

2. Fishbane S, et al. N Engl J Med. 2020;382:222-232

3. Topf J, et al. Kidney Med. 2022;4(8):100512

4. Korsuva. Package insert. Cara Therapeutics, Inc.; 2021

5. Kapruvia. Summary of product characteristics. Vifor Fresenius Medical Care Renal Pharma France; 2022

6. Kim BS, et al. Oral difelikefalin reduces pruritus in atopic dermatitis. Presented at: the 30th European Academy of Dermatology and Venereology Congress; September 29–October 2, 2021

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 > >>